EVIDENCE UPDATE · 2026

EMDR research in 2026: what changed and what did not

A new publication does not always carry the same weight: a guideline, meta-analysis, definitive trial, feasibility study and protocol answer different questions. This update summarises recent signals without turning headlines into recommendations.

Written and reviewed by EMDR Match Editorial Team27 August 2026Identified clinical sources · no individual clinical review claimed

Short answer

Research published in 2025–2026 reinforces that EMDR may reduce PTSD symptoms compared with waiting list or usual care, while some reviews rate certainty as low or very low and find no clear advantage over trauma-focused CBT. It also exposes an important gap: adverse effects are insufficiently measured and reported. New studies beyond PTSD remain largely preliminary.

PTSD: the comparator changes the conclusion

A review of trials against waiting list found favourable signals for symptoms and diagnostic remission, but rated certainty low or very low and noted missing outcomes on quality of life, acceptability and adverse effects.

Another recent review including comparisons with trauma-focused CBT found improvement over waiting or usual care and no significant difference between EMDR and trauma-focused CBT. Beating a waiting list does not establish superiority over another active treatment.

Safety: missing data is not evidence of no harm

The 2026 review examined 51 randomised trials included in recent meta-analyses. Only nine mentioned adverse effects and only one used systematic assessment.

Reported effects were generally mild and temporary, but missing criteria and monitoring prevent a reliable risk estimate. Informed consent and monitoring should not rely only on dropout or anecdotes.

Group protocols and new uses

The G-TEP meta-analysis pooled twelve studies and found a large association with reduced PTSD symptoms. Heterogeneity, comparators, populations, follow-up and risk of bias still matter before generalising to every group.

For functional neurological disorder, one randomised study established feasibility and clinical signals, not definitive efficacy. Other recent trials or protocols in infertility, eating or medical conditions do not automatically make EMDR a primary treatment.

How to read the next headline

Check whether the publication is a protocol or result, how many people participated, which comparator was used, what the primary outcome was, how long follow-up lasted and whether harms were measured.

Then look for replication, an independent systematic review and a clinical guideline. “Statistically significant”, “promising” and “recommended” are not synonyms.

FAQ

Frequently asked questions

Does 2026 research show EMDR is better than CBT?

No. A recent review found no significant difference from trauma-focused CBT, while both improved PTSD symptoms.

Are EMDR adverse effects well understood?

Not sufficiently. One review found that most analysed trials did not report them and almost none assessed them systematically.

Does one new trial make a use recommended?

No. Design, size, comparator, replication, certainty, harms and guidelines matter. A feasibility study or protocol does not establish efficacy.

Sources and scope

Informational content based on guidelines and professional bodies. It does not diagnose, recommend individual treatment or replace clinical assessment.